Table 1.
Estimate of the burden of fungal diseases in Burkina Faso.
| Underlying Condition | Assumed Incidences Used for the Calculation of Fungal Burden with References | Fungal Infections | Annual Incidence | Rate/100 K |
|---|---|---|---|---|
| Respiratory diseases | CPA: assumes that TB is the underlying cause of CPA in 80% TB: prevalence: 5800 (notified)–9400 (estimated); 0.85 with pulmonary involvement; 0.93 with pulmonary cavity; 15% mortality rate |
CPA | 1120 1 | 28.2 |
| CPA: incidence in cavitary TB: 0.12–0.22; incidence in non-cavitary TB: 0.01–0.04 SAFS: Asthma: 0.0226 of adult population [6] |
SAFS | 7429 | 41 | |
| 1/3 of the 10% worst asthmatic patients develop SAFS ABPA: 0.025 of adult asthmatic pts [7] |
ABPA | 5628 | 31.1 | |
| AIDS | 95,000 HIV+/AIDS pts [29] 57% not receiving ARV with CD4 cell count <350/mm3 Oral candidiasis: 90% of HIV pts with <200 CD4 [30] |
OPC | 24,300 | 134 |
| Oesophageal candidiasis: 20% of pts not on ARVs and CD4 <200, and 0.5% of those on ARVs [31] | Oesophageal candidiasis | 7450 | 41.1 | |
| Cryptococcosis: incidence 0.034 [13] | Cryptococcosis | 459 | 2.5 | |
| Pneumocystosis: incidence 0.095 [32] | Pneumocystosis | 1013 | 5.6 | |
| Care-associated infections | Invasive aspergillosis: 10% of haematological malignancies | Invasive aspergillosis | 54 | 0.3 |
| AL mean incidence: 0.0135 [23] | Candidemia | 906 | 5.0 | |
| Invasive candidiasis: Candidemia: 3.5% of cancer pts, 1.5% of surgical/ICU pts [24] + Peritonitis: 0.5*candidemia cases of surgical/ICU pts [33] | Candida peritonitis | 136 | 0.75 | |
| Mucosal, skin, and superficial fungal infections | RVVC: roughly 6% of adult women [8] | RVVC | 179,002 | 1977 |
| Tinea capitis: assumes a 13.9% prevalence in children under 16 [25] | Tinea capitis | 1,132,781 | 6255 | |
| Total | 1,360,280 |
1 Prevalence. pts: patients. AL: Acute Leukemia. CPA: Chronic Pulmonary Aspergillosis. OPC: Oro-Pharyngeal Candidiasis. SAFS: Severe Asthma with Fungal Sensitization. RVVC: Recurrent Vulvo-Vaginal Candidiasis; * mean time.